Journal Watch · The Lancet · 2026
Heart failure with reduced ejection fraction.
This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.
TL;DR
This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.
Key findings
- Despite advances in management, heart failure remains a leading cause of cardiovascular morbidity and mortality, partly due to absence of implementation of, and poor adherence to, medications.
- Future directions to improve outcomes include the integration of personalised medicine approaches, multiomic profiling, and innovative clinical trial designs to address residual risk and identify novel therapeutic targets.
- This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Approximately half of all heart failure cases are attributed to reduced left ventricular systolic function-classified as heart failure with reduced ejection fraction (HFrEF). Current guideline-directed medical therapy has markedly improved survival and quality of life for patients with HFrEF. Contemporary management emphasises early initiation and rapid uptitration of four foundational drug classes-renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors, β blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors-alongside diuretics for the symptom relief of volume overload.
Full abstract (original)
Background: Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in Europe and North America and approximately 1% in Asia and South America. Accurate diagnosis relies on the presence of typical signs and symptoms, elevated natriuretic peptide concentrations, and evidence of cardiac structural or functional abnormalities using cardiac imaging techniques.
What they did: Approximately half of all heart failure cases are attributed to reduced left ventricular systolic function-classified as heart failure with reduced ejection fraction (HFrEF). Current guideline-directed medical therapy has markedly improved survival and quality of life for patients with HFrEF. Contemporary management emphasises early initiation and rapid uptitration of four foundational drug classes-renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors, β blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors-alongside diuretics for the symptom relief of volume overload.
Results & conclusions: Despite advances in management, heart failure remains a leading cause of cardiovascular morbidity and mortality, partly due to absence of implementation of, and poor adherence to, medications. Future directions to improve outcomes include the integration of personalised medicine approaches, multiomic profiling, and innovative clinical trial designs to address residual risk and identify novel therapeutic targets. This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.
Abstract © the authors / The Lancet (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/s0140-6736(25)01851-3 · PubMed 41319669.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
Frequently asked questions
What did this The Lancet study find?
This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.
What type of study is this?
It is a review / perspective, published in The Lancet in 2026. Approximately half of all heart failure cases are attributed to reduced left ventricular systolic function-classified as heart failure with reduced ejection fraction (HFrEF).
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/s0140-6736(25)01851-3. PubMed ID: 41319669. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/heart-failure-with-reduced-ejection-fraction-018513/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides